Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma

被引:0
|
作者
Gallowitsch, HJ [1 ]
Mikosch, P [1 ]
Kresnik, E [1 ]
Unterweger, O [1 ]
Gomez, I [1 ]
Lind, P [1 ]
机构
[1] Landeskrankenhaus Klagenfurt, Abt Nukl Med, Dept Nucl Med & Special Endocrinol, A-9020 Klagenfurt, Austria
来源
JOURNAL OF NUCLEAR MEDICINE | 1998年 / 39卷 / 05期
关键词
thyroid carcinoma; iodine-131; technetium-99m-tetrofosmin; whole-body scan;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Determination of thyroglobulin (Tg) levels, determined under endogenous thyroid-stimulating hormone stimulation after withdrawal of L-thyroxin treatment (off-T4), has been proven to be the most sensitive method for evaluation of patients with recurrent malignancy or distant metastases. This study uses a comparative approach between low-dose I-131 scan and the previously reported highly sensitive Tc-99m-tetrofosmin whole-body scintigraphy, using Tg-off-T4 as a basis for comparison. Methods: Fifty-eight consecutive patients of our follow-up program with primary thyroid carcinoma ablated with thyroidectomy and radioiodine therapy were examined after L-thyroxin withdrawal over 3-4 wk with I-131 (185 MBq) and Tc-99m-tetrofosmin whole-body scintigraphy and Tg determination (off-T4) within 5 days. Patients with Tg levels above 0.5 ng/ml were defined as Group A (n = 29). Group B (n = 29) comprised patients who had Tg levels (off-T4) below 0.5 ng/ml. Results: Iodine-131 revealed only 19 of 44 tumor sites (43.18%). Additionally, three remnants could be demonstrated. Sensitivity showed decreasing values for local recurrences (4 of 7, 57.1%), bone lesions (7 of 13, 53.85%) and mediastinal (2 of 4, 50%), lung parenchymal (3 of 7, 42.85%) and lymph node (2 of 9, 22.2%) metastases. Whole-body scintigraphy with Tc-99m-tetrofosmin revealed a total of 39 of 44 malignant lesions (88.6%). Sensitivity was superior for lung parenchymal metastases (9 of 9, 100%), mediastinum (4 of 4, 100%) and lymph nodes (9 of 10, 90%) and inferior for bone metastases (11 of 13, 84.6%). Local recurrences could be detected in 6 of 7 patients (85.7%), and thyroid remnants were detected in 2 cases (2 of 11, 18.2%). One liver metastasis could not be detected because of the physiologic tracer distribution of Tc-99m-terofosmin. Thyroglobulin-off-TLF detected malignant recurrence or metastases in 18 of 19 patients (94.7%) when a cutoff of 3 ng/ml was used and in 16 of 19 patients (84.2%) when a cutoff of 10 ng/ml was used. Specificity was calculated as 71.8% when a cutoff of 0.5 ng/ml was used, 89.7% when a cutoff of 3 ng/ml was used and 100% when a cutoff of 10 ng/ml was used. Conclusion: Scintigraphy with Tc-99m-tetrofosmin showed clear advantages concerning sensitivity in most metastatic lesions when compared with low-dose I-131 scan. Despite a slight lower specificity, Tc-99m-tetrofosmin whole-body scintigraphy has, therefore, been proven to be a useful tool in the assessment of metastatic lesions in differentiated thyroid carcinoma.
引用
收藏
页码:870 / 875
页数:6
相关论文
共 50 条
  • [1] Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma
    Lind, P
    Gallowitsch, HJ
    Langsteger, W
    Kresnik, E
    Mikosch, P
    Gomez, I
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (03): : 348 - 352
  • [2] Iodine-131 whole-body scintigraphy differentiated thyroid carcinoma
    Verburg, Frederik A.
    Gruenwald, Frank
    Lassmann, Michael
    Haenscheid, Heribert
    Luster, Markus
    Dietlein, Markus
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (04): : 124 - 136
  • [3] Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases
    Ünal, S
    Menda, Y
    Adalet, I
    Boztepe, H
    Özbey, N
    Alagöl, F
    Cantez, S
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (11): : 1897 - 1902
  • [4] Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma
    Franceschi, M
    Kusic, Z
    Franceschi, D
    Lukinac, L
    Roncevic, S
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (03): : 446 - 451
  • [5] Guidelines for iodine-131 whole-body scintigraphy in differentiated thyroid cancer
    Dietlein, M
    Dressler, J
    Eschner, W
    Leisner, B
    Reiners, C
    Schicha, H
    [J]. NUKLEARMEDIZIN, 1999, 38 (6A) : 213 - 214
  • [6] Procedural guideline for Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (version 5)
    Verburg, Frederik A.
    Schmidt, Matthias
    Kreissl, Michael C.
    Gruenwald, Frank
    Lassmann, Michael
    Haenscheid, Heribert
    Hohberg, Melanie
    Luster, Markus
    Dietlein, Markus
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (03): : 228 - 241
  • [7] Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases
    Filesi, M
    Signore, A
    Ventroni, G
    Melacrinis, FF
    Ronga, G
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (09): : 1542 - 1546
  • [8] Technetium-99m tetrofosmin uptake in insular thyroid carcinoma - A comparison with iodine-131
    Degirmenci, B
    Aydin, A
    Comlekci, A
    Ozdogan, O
    Bekis, R
    [J]. CLINICAL NUCLEAR MEDICINE, 2003, 28 (05) : 385 - 388
  • [9] Assessment of thyroid nodules by technetium-99m-tetrofosmin scintigraphy
    Akcay, G
    Uslu, H
    Varoglu, E
    Tekin, SB
    Gundogdu, C
    [J]. BRITISH JOURNAL OF CLINICAL PRACTICE, 1997, 51 (01): : 5 - 7
  • [10] Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2*)
    Dietlein, M
    Dressler, J
    Eschner, W
    Leisner, B
    Reiners, C
    Schicha, H
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2003, 42 (03): : 123 - 125